Rana Mohamed
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Rana Mohamed has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
- Alex Shipe
Department of Surgery , University of Wisconsin-Madison , 600 Highland Ave, Madison 53792 , Wisconsin, USA , wisc.edu
1 shared publication - Andrew J. Lail
Department of Pathology and Laboratory Medicine , University of Wisconsin-Madison , 5510 Element Way, Madison 53719 , Wisconsin, USA , wisc.edu
1 shared publication - Angela Gifford
Department of Surgery, University of Wisconsin-Madison, 600 Highland Ave, Madison, WI 53792
1 shared publication - David H. O'COnnor
Department of Pathology and Laboratory Medicine, University of Wisconsin-Madison, Madison, Wisconsin, United States of America
1 shared publication - Isla E. Emmen
Department of Pathology and Laboratory Medicine, University of Wisconsin-Madison, Madison, WI, USA
1 shared publication - Jacqueline Garonzik-Wang
Department of Surgery, University of Alabama at Birmingham Heersink School of Medicine, Birmingham, Alabama, USA; Comprehensive Transplant Institute, University of Alabama at Birmingham, Birmingham, Alabama, USA
1 shared publication
Latest Publications
- Open Access
- 1 January 2026
- Published by Wiley in Case Reports in Infectious Diseases
- Vol. 2026 (1) , 6154094
Describing a Persistent SARS‐CoV‐2 Infection Outcomes and Mutations Associated With B‐Cell Deficiency: A Case Report
Background: Immunocompromised (IC) individuals are at an increased risk for persistent SARS‐CoV‐2 infections and can develop new viral mutations and lineages not seen in the community. In this case report, a persistent SARS‐CoV‐2 infection (330 days) in an IC patient is examined for viral mutations and mutations associated with cryptic lineages. Case Presentation: The patient was followed up in a longitudinal study examining persistent SARS‐CoV‐2 in IC patients. The patient provided stool and nasal swab samples biweekly until 28 days postenrollment, then monthly, and then quarterly after 12 months post enrollment until the participant was no longer positive for SARS‐CoV‐2. Staff performed RT‐qPCR and viral sequencing on the samples. Viral mutations from the XBK lineage were already present in the initial sample. By the end of the infection period, there were 40 fixed consensus changes from XBK of which two mutations were typical for cryptic lineages. Mutations increased steadily over time, with most mutations fixed by day 253, including the cryptic typical mutations. Conclusion: This case demonstrates the potential for persistent SARS‐CoV‐2 infections to develop mutations and lineages in IC patients and highlights the need for continued SARS‐CoV‐2 monitoring and treatment in this vulnerable population.
- 1 January 2026
- Published by Wiley in Case Reports in Infectious Diseases
- Vol. 2026 (1) , 6154094
Open AccessDescribing a Persistent SARS‐CoV‐2 Infection Outcomes and Mutations Associated With B‐Cell Deficiency: A Case Report
Background: Immunocompromised (IC) individuals are at an increased risk for persistent SARS‐CoV‐2 infections and can develop new viral mutations and lineages not seen in the community. In this case report, a persistent SARS‐CoV‐2 infection (330 days) in an IC patient is examined for viral mutations and mutations associated with cryptic lineages. Case Presentation: The patient was followed up in a longitudinal study examining persistent SARS‐CoV‐2 in IC patients. The patient provided stool and nasal swab samples biweekly until 28 days postenrollment, then monthly, and then quarterly after 12 months post enrollment until the participant was no longer positive for SARS‐CoV‐2. Staff performed RT‐qPCR and viral sequencing on the samples. Viral mutations from the XBK lineage were already present in the initial sample. By the end of the infection period, there were 40 fixed consensus changes from XBK of which two mutations were typical for cryptic lineages. Mutations increased steadily over time, with most mutations fixed by day 253, including the cryptic typical mutations. Conclusion: This case demonstrates the potential for persistent SARS‐CoV‐2 infections to develop mutations and lineages in IC patients and highlights the need for continued SARS‐CoV‐2 monitoring and treatment in this vulnerable population.